Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02356549 · ClinicalTrials.gov registry record · NA
African American Cancer Clinical Trial Decisions: Testing Tailored Messages
A NA study of Lymphoma and Leukemia, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT02356549: Completed NA study of Lymphoma and Leukemia, sponsored by Virginia Commonwealth University.
NCT02356549 is a NA study of Lymphoma and Leukemia that has completed, run by Virginia Commonwealth University. The registered enrollment target is 90 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02356549, a NA study of Lymphoma and Leukemia, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the use of tailored health messages and/or involving physicians are effective in increasing African American (AA) patient activation in a clinical trial consultation. The proposal will use a composite score for patient activation derived from the Street Patient Activation Coding system. This will help to determine the effectiveness of our intervention on patient activation and patient centered clinical trial decision.
Primary Outcome
Randomized clinical trial (using a 2x2 factorial design) to inform our knowledge of the efficacy of a tailored health message intervention, using different depths of tailoring and involving physicians, on AA cancer patients' active communication in CT consultations. In this study AA cancer patients will be randomized into one of four experimental groups. Scientifically determine the effectiveness of our intervention by using a composite score for patient activation derived from the Street Patien
Interventions
- BEHAVIORAL EMR Tailoring
- BEHAVIORAL Survey Tailoring
- BEHAVIORAL Physician Involvement
Study Locations (1)
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2020-03-06 |
| Phase | NA |
What the finished NCT02356549 record still lists
NCT02356549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which EMR Tailoring is the first listed.
NCT02356549 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02356549 about?
NCT02356549 is a clinical study titled "African American Cancer Clinical Trial Decisions: Testing Tailored Messages". The purpose of this study is to determine if the use of tailored health messages and/or involving physicians are effective in increasing African American (AA) patient activation in a clinical trial consultation. The proposal will use a composite score for patient activation derived from the Street P...
What is the current status of trial NCT02356549?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2015-05-01. Estimated completion is 2020-03-06.
What conditions does trial NCT02356549 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myeloma.
What interventions are being tested in trial NCT02356549?
The interventions under investigation include: EMR Tailoring (BEHAVIORAL), Survey Tailoring (BEHAVIORAL), Physician Involvement (BEHAVIORAL).
Who is sponsoring clinical trial NCT02356549?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02356549 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02356549's enrollment target sits among peer trials
90 93rd of 299 higher than 206 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI